

09 Jul 2023 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: new AstraZeneca ADC lung cancer data seen as underwhelming; William Pao's aspirations at Pfizer; Scholar Rock's hopes for SMA asset; Biomarin's Roctavian launch; and Indian lighthouses deliver gains.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 7 July 2023, including: new [*AstraZeneca PLC*](#) ADC lung cancer data seen as underwhelming; William Pao's aspirations at [*Pfizer Inc.*](#); [*Scholar Rock, LLC*](#)'s hopes for SMA asset; [*Biomarin Pharmaceutical Inc.*](#)'s Roctavian launch; and Indian lighthouses deliver gains.

This and all our other podcasts are available on the Pharma Intelligence channel on [*Apple Podcasts*](#), [*Google Podcasts*](#), [*SoundCloud*](#), [*TuneIn*](#) and [*Spotify Podcasts*](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[*AstraZeneca's Dato-DXd Falls Short Of Great Expectations In Lung Cancer Study*](#)" - Scrip, 3 Jul, 2023.)

(Also see "[*William Pao On Pfizer's 'Aspirational' Drug Development Goal, Seagen And More*](#)" - Scrip, 5 Jul, 2023.)

(Also see "[*Scholar Rock Looks To Augment Existing Therapies In Spinal Muscular Atrophy*](#)" - Scrip, 3 Jul, 2023.)

(Also see "[*Its Gene Therapy Roctavian Finally Approved With \\$2.9m Price, BioMarin Aims To Prove Doubters Wrong*](#)" - Scrip, 30 Jun, 2023.)

(Also see "[*Indian 'Lighthouses' Deliver Gains Amid Price Erosion, Rising Input Costs*](#)" - Scrip, 3 Jul, 2023.)

[Click here to explore this interactive content online](#) ✎